Intrexon Corp. (NYSE:XON) shares were up 2.5% during mid-day trading on Monday . The company traded as high as $25.40 and last traded at $25.16, with a volume of 397,861 shares trading hands. The stock had previously closed at $24.55.

A number of research analysts recently issued reports on XON shares. Zacks Investment Research upgraded Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a report on Tuesday. Stifel Nicolaus reiterated a “buy” rating on shares of Intrexon Corp. in a report on Thursday, April 21st. Wunderlich reiterated a “buy” rating and issued a $50.00 target price on shares of Intrexon Corp. in a report on Thursday, July 7th. Griffin Securities reiterated a “buy” rating and issued a $65.00 target price on shares of Intrexon Corp. in a report on Tuesday, June 7th. Finally, JMP Securities started coverage on Intrexon Corp. in a report on Tuesday, May 3rd. They issued an “outperform” rating and a $42.00 target price for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $49.66.

The firm’s 50 day moving average price is $25.89 and its 200-day moving average price is $29.74. The firm’s market cap is $2.73 billion.

Intrexon Corp. (NYSE:XON) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.35. During the same period in the previous year, the business earned $0.25 EPS. The business earned $43.40 million during the quarter, compared to the consensus estimate of $46.26 million. The business’s revenue was up 28.4% compared to the same quarter last year. On average, equities analysts predict that Intrexon Corp. will post ($1.32) EPS for the current year.

In other Intrexon Corp. news, CEO Randal J. Kirk purchased 41,830 shares of the business’s stock in a transaction on Friday, May 13th. The stock was bought at an average cost of $23.92 per share, for a total transaction of $1,000,573.60. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

A number of hedge funds and institutional investors have modified their holdings of the stock. Morgan Stanley increased its position in shares of Intrexon Corp. by 12.6% in the fourth quarter. Morgan Stanley now owns 3,162,236 shares of the company’s stock valued at $95,342,000 after buying an additional 354,559 shares during the period. Oracle Investment Management Inc. increased its position in shares of Intrexon Corp. by 15.9% in the fourth quarter. Oracle Investment Management Inc. now owns 932,585 shares of the company’s stock valued at $28,117,000 after buying an additional 127,708 shares during the period. Trexquant Investment LP acquired a new position in shares of Intrexon Corp. during the fourth quarter valued at $2,590,000. California State Teachers Retirement System increased its position in shares of Intrexon Corp. by 7.2% in the fourth quarter. California State Teachers Retirement System now owns 90,526 shares of the company’s stock valued at $2,729,000 after buying an additional 6,078 shares during the period. Finally, New York State Common Retirement Fund increased its position in shares of Intrexon Corp. by 30.1% in the fourth quarter. New York State Common Retirement Fund now owns 212,875 shares of the company’s stock valued at $6,418,000 after buying an additional 49,290 shares during the period.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.